《Table 5 Comparison between parameters determined at 24±6 wk from start of ustekinumab therapy betwe

《Table 5 Comparison between parameters determined at 24±6 wk from start of ustekinumab therapy betwe   提示:宽带有限、当前游客访问压缩模式
本系列图表出处文件名:随高清版一同展现
《Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease》


  1. 获取 高清版本忘记账户?点击这里登录
  1. 下载图表忘记账户?点击这里登录

In conclusion,our data strongly suggest that ustekinumab is effective in treatmentrefractory,moderate to severe CD under“real-world”conditions.In particular,more data is needed on the long-term safety of this drug and on potential predictors of response.